As a specialized US-based supplier of high-purity research compounds, PX1 Research provides analytical-grade Bronchogen to academic and institutional laboratories evaluating short bioregulatory peptides. Qualified research institutions can access fully verified lot documentation, HPLC mass spectrometry reports, and endotoxin screening to support reproducible in vitro and preclinical models.
As a specialized US-based supplier of high-purity research compounds, PX1 Research provides analytical-grade Bronchogen to academic and institutional laboratories evaluating short bioregulatory peptides. Qualified research institutions can access fully verified lot documentation, HPLC mass spectrometry reports, and endotoxin screening to support reproducible in vitro and preclinical models.
A qualified Bronchogen defensive function supplier provides ultra-pure, synthetically derived short peptide bioregulators (specifically the tetrapeptide sequence Ala-Asp-Glu-Leu) manufactured under strict quality standards for in vitro and animal research into pulmonary epithelial defense, tissue homeostasis, and cellular barrier function.
When sourcing Bronchogen for experimental protocols, investigators require rigorous analytical validation to ensure target specificity and batch-to-batch consistency. PX1 Research fulfills these requirements by offering USA-manufactured compounds validated via High-Performance Liquid Chromatography (RP-HPLC), Mass Spectrometry (MS), and quantitative endotoxin testing. Every sequence provided through our catalog of research peptides is strictly intended for scientific laboratory evaluation and non-clinical experimentation.
Bronchogen is a synthetic short-chain peptide bioregulator modeled after endogenous chromatin-modulating signaling molecules identified in bronchial tissue. Composed of four amino acid residues (L-alanidyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine), Bronchogen belongs to a distinct class of peptide bioregulators that interact directly with nucleosomal DNA and histones to modulate gene expression pathways responsible for tissue-specific protein synthesis.
In preclinical investigations, short peptides like Bronchogen are evaluated for their potential to penetrate nuclear membranes and bind specifically to complementary nucleotide motifs within promoter regions. Preclinical studies suggest that this interaction alters chromatin conformation, facilitating access for transcription factors involved in tissue remodeling, antioxidant defense enzymes, and structural protein expression in bronchial epithelial cell lines.
Unlike large polypeptide growth factors or monoclonal antibodies, Bronchogen's low molecular weight minimizes steric hindrance, making it an ideal candidate for molecular dynamics modeling, nuclear translocation assays, and cellular stress response experiments within our peptide research library.
Scientific interest in Bronchogen centers primary on its capacity to preserve structural and functional defense mechanisms in pulmonary tissues subjected to oxidative, toxic, or inflammatory challenges. In vitro models utilizing human primary bronchial epithelial cells (PBECs) demonstrate that exposure to Bronchogen modulates the expression of tight junction proteins, including claudins and occludins, which maintain transepithelial electrical resistance (TEER) across mucosal barriers.
In rodent models of induced pulmonary injury or chronic environmental stress, researchers have observed that administration of short bioregulators corresponds with attenuated neutrophil infiltration, altered pro-inflammatory cytokine secretion (such as IL-6 and TNF-alpha), and enhanced expression of endogenous antioxidant enzymes including superoxide dismutase (SOD) and glutathione peroxidase.
Furthermore, animal studies indicate that Bronchogen may influence surfactant protein gene expression in type II alveolar cells, supporting structural stability in distal airway models. Researchers seeking to replicate these findings rely on consistent chemical identity, which is why sourcing from a verified supplier of analytical-grade Bronchogen 10mg is essential for publishing reproducible data.
To properly position Bronchogen within cellular defense research protocols, laboratory investigators frequently compare its mechanism against other short-chain peptide bioregulators and immune-modulating compounds within the peptide family.
While Bronchogen specifically targets pulmonary and bronchial epithelial signaling, the dipeptide Vilon research overview (Lys-Glu) is primary evaluated for systemic immune response modulation and T-cell chromatin remodeling. Similarly, Thymogen research profile focuses on thymic factor expression and cellular immunity, whereas Epitalon telomerase research (Ala-Glu-Asp-Gly) is investigated for pineal gland function and telomerase activity.
Understanding these structural and tissue-specific differences allows principal investigators to select the appropriate candidate sequence when designing multi-target bioregulatory experiments or assessing broad-spectrum cytoprotectants from our broader short peptide bioregulators category.
Evaluating a supplier for defensive function peptide research requires looking beyond surface-level chemical specifications. Laboratories must demand comprehensive analytical transparency to guarantee that experimental anomalies stem from biological variables rather than reagent contamination or peptide degradation.
Key quality benchmarks for sourcing Bronchogen include:
1. Purity Verification via RP-HPLC: Assays must demonstrate single-peak chromatographic purity exceeding 98.0%, ensuring the absence of truncated sequences, deletion peptides, or residual protecting groups from solid-phase peptide synthesis (SPPS).
2. Exact Mass Confirmation via Mass Spectrometry: Electrospray ionization mass spectrometry (ESI-MS) or MALDI-TOF must confirm the exact monoisotopic mass of the peptide sequence, confirming accurate synthesis without amino acid substitution.
3. Quantitative Endotoxin Testing: Bacterial endotoxins (lipopolysaccharides) can confound cell culture assays and animal cytokine profiles. Qualified suppliers must perform Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels below 0.5 EU/mg.
4. Lot-Specific Traceability: Chemical lots must feature individual Certificate of Analysis (COA) documentation generated by an independent, ISO 17025 accredited laboratory.
PX1 Research adheres strictly to these standards, providing USA-manufactured materials backed by complete analytical documentation for institutional procurement through our institutional supply and wholesale accounts.
To preserve the structural integrity of synthetic Bronchogen in laboratory environments, strict handling and reconstitution protocols must be followed. Lyophilized Bronchogen is supplied as a sterile, vacuum-sealed peptide cake requiring precise solution preparation prior to in vitro application.
Reconstitution should be conducted using sterile, bacteriostatic or laboratory-grade water, or sterile phosphate-buffered saline (PBS, pH 7.4), depending on the requirements of the downstream assay. Rapid dissolution typically occurs due to the hydrophilic nature of the Asp and Glu residues within the Ala-Asp-Glu-Leu sequence.
For optimal stability, lyophilized vials should be stored at -20°C or -80°C upon receipt, protected from moisture and direct light exposure. Following reconstitution, liquid aliquots should be frozen immediately to avoid repeated freeze-thaw cycles, which can induce physical peptide aggregation or peptide bond cleavage over prolonged periods.
A rigorous Certificate of Analysis acts as the standard of quality assurance for any research chemical. When evaluating COA documentation for Bronchogen, laboratory directors should scrutinize several key analytical fields.
The High-Performance Liquid Chromatography spectrum should show a single sharp principal peak, with minor background integration representing less than 1-2% total area. Mass spectrum output must display the molecular ion peak corresponding to the predicted formula (C18H29N4O9 for the primary tetrapeptide structure) without secondary adduct peaks or unexpected fragment ion signals.
Additionally, residual solvent analysis and counter-ion content (such as trifluoroacetate or acetate salts remaining from purification elution) must be documented to allow investigators to adjust concentration calculations accurately in sensitive cellular models.
PX1 Research maintains a fully integrated domestic supply chain designed to support the demanding schedules of academic and commercial research programs. All peptide synthesis, purification, lyophilization, and secondary packaging operations take place in state-of-the-art, GMP-compliant facilities within the United States.
To streamline logistics and prevent supply disruption, inventory is distributed directly from dispatch centers located in California and Arizona. Orders placed Monday through Friday before cut-off times qualify for same-day dispatch, ensuring fast transit times and reduced cold-chain exposure.
By eliminating overseas transit delays and unverified third-party brokers, PX1 Research provides institutional buyers with stable pricing, batch consistency, and direct access to technical support for all experimental peptide requirements.
What is Bronchogen designated for in research settings?
Bronchogen is supplied strictly as a research-grade chemical for in vitro, biochemical, and animal tissue studies investigating short bioregulatory peptide signaling, bronchial epithelial cell dynamics, and respiratory defensive function. It is not intended for human or veterinary use.
What amino acid sequence constitutes synthetic Bronchogen?
Bronchogen is a synthetic tetrapeptide comprised of the sequence L-alanidyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Ala-Asp-Glu-Leu).
How does PX1 Research verify Bronchogen batch purity?
Every lot of Bronchogen undergoes rigorous analytical testing including Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity assessment, Mass Spectrometry (MS) for exact sequence verification, and quantitative LAL testing for bacterial endotoxins.
Where are PX1 Research peptides synthesized and shipped from?
All PX1 Research compounds are manufactured in domestic, GMP-compliant facilities within the USA and shipped directly from fulfillment hubs in California and Arizona.
What solvent is recommended for reconstituting Bronchogen in a lab setting?
Bronchogen reconstitutes readily in sterile laboratory-grade water, sterile normal saline, or phosphate-buffered saline (PBS, pH 7.4), depending on the specific requirements of the cell culture or assay protocol.
How should long-term storage of lyophilized Bronchogen be managed?
Lyophilized Bronchogen should be stored in a desiccated environment at -20°C or -80°C to ensure long-term stability. Avoid exposure to heat, light, and ambient humidity.
Are batch-specific Certificates of Analysis provided with orders?
Yes. Every shipment includes access to third-party, lot-specific Certificates of Analysis detailing HPLC purity chromatograms, mass spec analysis, and endotoxin metrics.
How does Bronchogen differ from other bioregulators like Vilon or Epitalon?
While Vilon (Lys-Glu) primary targets systemic immune models and Epitalon (Ala-Glu-Asp-Gly) focuses on telomerase dynamics, Bronchogen (Ala-Asp-Glu-Leu) is studied specifically for its localized gene-modulating effects in bronchial and pulmonary epithelial tissues.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.